BioInvent International AB of Sweden has appointed Anna Wickenberg, previously with Teva Pharmaceuticals, as vice president of clinical development. In this role she will sit on the management group and report to the chief executive Michael Oredsson.
Dr Wickenberg was most recently responsible for the clinical development of a compound for an orphan indication within neurology for Teva. She has 15 years of experience in clinical development and holds a PhD in medical sciences and immunology and an MSc in molecular biology.
BioInvent announced the appointment on 22 January 2015.
Copyright 2015 Evernow Publishing Ltd